At CRISPR Therapeutics, we are focused on developing transformative gene-based medicines for serious human diseases We are rapidly translating our specific, efficient and versatile CRISPR/Cas9 gene-editing platform into therapies to treat hemoglobinopathies, cancer, diabetes and other diseases Our multi-disciplinary team of world-class researchers and drug developers works every day to translate our CRISPR/Cas9 technology into breakthrough human therapeutics. Our lead program targeting the blood diseases β-thalassemia and sickle cell disease has entered clinical testing, as has our first allogeneic CAR-T program targeting B-cell malignancies. We are also advancing additional blood stem cell, immuno-oncology, regenerative medicine and in vivo programs towards the clinic.
🏢 Is this your organization?
We list organizations free for now. Claim this page to keep your details accurate and to receive enquiries sent from it by 4IRW visitors. Once we have verified you, we can update your details and add services, photos and prices.
Your request has been submitted successfully.
-
MIT nanotech creates personalized cancer
Breakthrough nanofiber platform for personali.
-
APOE4 Gene Disrupts Neuron Insulation Re
What the MIT discovery reveals about APOE4, m.
-
Soft Robot Enteroscope Enables Precise S
Reinventing Small-Intestine Access with a Sof.
-
Secure Key-Management Architecture Boost
Why a New Key-Management Architecture Matters.
-
Superhuman Hearing AI Advances Speech an
From Classical Guitar to Superhuman Listening.
